<DOC>
	<DOC>NCT00244725</DOC>
	<brief_summary>Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.</brief_summary>
	<brief_title>Odiparcil For The Prevention Of Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Women must be unable to have children. Will have a total knee replacement. Allergic to any Xray dye. Allergies or reactions to warfarin or coumadin. Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT). On anticoagulation therapy. Renal impairment. Participated in any clinical trial in the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>PE</keyword>
	<keyword>total knee replacement</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>VTE</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>DVT</keyword>
	<keyword>deep vein thrombosis</keyword>
</DOC>